The British HIV Association national audit on the management of subjects co-infected with HIV and hepatitis B/C

The aim of this work was to survey current service provision and adherence to the British HIV Association (BHIVA) guidelines for the management of HIV and hepatitis B/C co-infected patients in the UK. Sites were invited to complete a survey of local care arrangements for co-infected patients. A case...

Full description

Saved in:
Bibliographic Details
Published in:International journal of STD & AIDS 2011-03, Vol.22 (3), p.173-176
Main Authors: Garvey, L, Curtis, H, Brook, G
Format: Article
Language:English
Subjects:
AIDS/HIV
Biological and medical sciences
Female
General aspects
Guideline Adherence
Health Care Surveys
Hepatitis B - epidemiology
Hepatitis B - therapy
Hepatitis B - virology
Hepatitis C - epidemiology
Hepatitis C - therapy
Hepatitis C - virology
HIV Infections - epidemiology
HIV Infections - therapy
HIV Infections - virology
Human viral diseases
Humans
Infectious diseases
Male
Medical Audit
Medical sciences
United Kingdom - epidemiology
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral hepatitis
Viral Vaccines - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this work was to survey current service provision and adherence to the British HIV Association (BHIVA) guidelines for the management of HIV and hepatitis B/C co-infected patients in the UK. Sites were invited to complete a survey of local care arrangements for co-infected patients. A case-note audit of all co-infected attendees during a six-month period in 2009 was performed. Data including demographics, clinical parameters, hepatitis disease status, antiretroviral and hepatitis B/C therapy were collected. Using BHIVA guidelines as audit standards, the proportion of sites and subjects meeting each standard was calculated. One-hundred and forty sites (75%) responded and data from 973 eligible co-infected patients were submitted. Approximately a third of sites reported not re-checking hepatitis serology or vaccination titres annually. Of all co-infected patients, 122 (13%) were neither vaccinated nor immune to hepatitis A and 26 (5%) of patients with hepatitis C were neither vaccinated nor naturally immune to hepatitis B. Of HBsAg-positive subjects, 25 (6%) were receiving lamivudine as the sole drug with antihepatitis B activity. In the UK, the management of HIV and hepatitis B/C co-infection remains highly variable. Optimizing the care of this high-risk patient group is a priority.
ISSN:0956-4624
1758-1052
DOI:10.1258/ijsa.2010.010380